CBIH · Cannabis Bioscience International Holdings, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The Company's history of recurring losses, negative working capital and negative cash flows from operating activities raises substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Apr 16, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $123.63K | $303.02K | $248.84K | $316.83K | |
| $26.23K | $40.11K | $45.6K | $93.45K | |
| $97.39K | $262.92K | $203.24K | $223.38K | |
| — | 86.76% | 81.68% | 70.5% | |
| $31.42K | $101.91K | $123.76K | $177.11K | |
| $496.21K | $684.28K | $689.38K | $1.21M | |
| -$398.82K | -$421.37K | -$486.14K | -$983.37K | |
| — | -139.05% | -195.36% | -310.38% | |
| $148.75K | $136.26K | $154.21K | $90.97K | |
| -$116.47K | -$127.46K | -$165.21K | -$49.21K | |
| — | — | $0 | $0 | |
| -$515.29K | -$548.82K | -$651.35K | -$1.03M | |
| — | -181.12% | -261.75% | -325.91% | |
| USD/shares | -$0.00 | -$0.00 | -$0.00 | -$0.00 |
| USD/shares | -$0.00 | -$0.00 | -$0.00 | -$0.00 |
| shares | — | 10.72B | 10.32B | 9B |
| shares | — | 10.72B | 10.32B | 9B |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 21 similar-size Drug Manufacturers - Specialty & Generic companies (of 98 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Clinical Trials | $301,731 | $213,865 | $267,220 |
| Merchandise | $1,291 | $4,410 | $22,300 |
| Consulting Fees | $0 | $28,641 | $8,333 |
| Seminar Fees | $0 | $1,925 | $16,433 |
| Video Course | — | — | $2,497 |
| Royalty | — | — | $42 |